Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz 400mg in Treatment-naïve Chinese HIV Patients
NCT04596488Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of efavirenz in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Peking Union Medical College Hospital. Primary endpoint: Viral suppression at 48 weeks. Started Jun 2017; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04596488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04596488.